Clinical Trial Detail

NCT ID NCT03743766
Title Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors John Kirkwood
Indications

melanoma

Therapies

Relatlimab

Nivolumab + Relatlimab

Nivolumab

Age Groups: adult senior

No variant requirements are available.